Loading...
Found 98 results for will-simon
A listing of will-simon medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiationfor the Treatment of Early-Stage Anal Cancer
A
Anita Turk, MD
Primary Objective:1. To determine the clinical complete response rate (cCR) assessed following weekly carboplatin and paclitaxel in combination with pembrolizumab and radiation for the treatment of early-stage anal cancer. Secondary Objectives:1. To assess the safety and tolerability of weekly carboplatin and paclitaxel in combination with pembrolizumab and radiation for the treatment …
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients with Locally Advanced or Metastatic Solid Tumors
G
Greg Durm, MD
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in patients with advanced or metastatic solid tumors. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive …
A Phase 3, Open-label, Multicenter, Randomized Trial of TrastuzumabDeruxtecan with Bevacizumab Versus Bevacizumab Monotherapy asFirst-line Maintenance Therapy in HER2-Expressing Ovarian Cancer.
J
Jessica Parker
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.Interested in participating? For more information about this research study …
Phase I/II Trial of Lurbinectedin with Osimertinib in Transformed Small Cell Lung Cancer
M
Misty D. Shields, MD, PhD
Primary Objective:To assess the efficacy of the combination of lurbinectedin with osimertinib in patients with EGFR altered non-small cell lung cancer (NSCLC) with documented transformation to SCLC, after the use of EGFR tyrosine kinase inhibitor osimertinib.Secondary ObjectiveTo evaluate the safety of the combination of lurbinectedin with osimertinib in patients with …
PSMAcTION: A phase II/III, open-label, international, multi-center, randomized study of AAA817 versus standard of care in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapy.
N
Nabil Adra, MD
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy.Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is …
A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
R
Rohan Maniar
What is the purpose of this study?This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC …
FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 Alterations
T
Tareq Salous
This is an open-label, multi-center, phase 1a/b study in participants with FGFR3-altered advanced solid tumors, including metastatic urothelial cancer (UC). The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that …
A Prospective Low-Interventional Phase 4 Single Arm Study of Ocular Assessments in Patients Treated with Tivdak® in Recurrent or Metastatic Cervical Cancer
S
Sharon E. Robertson
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to …
PATIENTS PERSPECTIVES ON TREATMENT DECISION-MAKING AND THE ACCEPTABILITY AND USABILITY OF THE INTERACTIVE WEB-ENABLED COMMUNICATION RESOURCES OF THE CLL/SLL CARE ROAD MAP
L
Larry Cripe, MD
The purpose of the study is to understand how people think about choosing between two or more treatment options and then to seek their reactions to the CLL Mind Map and Patient First Resources. Interested in participating? For more information about this research study or other cancer-related clinical trials at Indiana …
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
U
Utpal Dave, MD
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. Usual treatment after a complete response may include observation or high dose chemotherapy followed by …
Please choose between Voice or SMS based delivery of verification code
or